APP下载

微生态制剂、蒙脱石散剂、干扰素三联法治疗小儿秋季腹泻的临床疗效观察

2012-09-03叶作文

中国当代医药 2012年21期
关键词:微生态制剂干扰素临床应用

叶作文

[摘要] 目的 觀察微生态制剂、蒙脱石散剂、干扰素三联法治疗小儿秋季腹泻的临床疗效。 方法 将84例患儿按随机数字表分为观察组42例和对照组42例,对照组口服蒙脱石散剂冲剂,肌内注射重组人干扰素,观察组在对照组基础上,口服枯草杆菌、肠球菌二联活菌多维颗粒剂(妈咪爱),<2周岁者每次1袋、1~2次/d,>2周岁者每次1~2袋、1~2次/d,3 d为1个疗程,观察治疗前后患儿症状改善情况,计算患儿症状复常时间与出院时间。 结果 (1)观察组的治愈率、总有效率分别为61.90%、95.24%,对照组的治愈率、总有效率分别为28.57%、76.19%,观察组的治愈率、总有效率均明显高于对照组,差异具有统计学意义(P < 0.05);(2)观察组的退热、大便次数复常、大便性状复常、粪便镜检复常、平均出院时间较对照组均明显缩短,各项指标差异均具有统计学意义(P < 0.05)。 结论 微生态制剂、蒙脱石散剂、干扰素三联法治疗小儿秋季腹泻临床疗效确切,可双向调节肠道菌群失调,改善肠道内环境,保护、修复受损黏膜,促进消化道上皮组织再生。

[关键词] 微生态制剂;蒙脱石散剂;干扰素;小儿秋季腹泻;临床应用

[中图分类号] R975+.3[文献标识码] A[文章编号] 1674-4721(2012)07(c)-0100-03

The effect observation of probiotics, montmorillonite powder and interferon in treatment of infantile autumn diarrhea

YE Zuowen

Pediatrics Department, Zijin County People's Hospital of Heyuan City in Guangdong Province, Zijin 517400, China

[Abstract] Objective To observe the effect of probiotics, montmorillonite powder and interferon in the treatment of infantile autumn diarrhea. Methods Eighty-four patients were divided into observation group (42 cases) and control group (42 cases), the control group was given montmorillonite powder granules and recombinant human interferon intramuscular injection, the observation group was given bacillus subtilis, enterococcus bivalent viable multidimensional granules oral on the basis of the control group, patients with the age < 2 years old were given 1 bag once, 1-2 times a day, the age > 2 years old were given 1-2 bags once, 1-2 times a day, both groups were treated for 3 days for a course, the symptoms were observed before and after treatment, and the symptoms recover time and discharge time were calculated. Results (1)The cure rate and the total efficiency of observation group were 61.90% and 95.24% respectively, that of the control group were 28.57% and 76.19%, the cure rate and total efficiency of the observation group was significantly higher than that of the control group, the difference was statistically significant (P < 0.05); (2)The time of fever recover, stool frequency normalization, normalization of stool consistency, stool microscopy normalization, and the average discharge time were significantly shorter than those of the control group, the differences were statistically significant (P < 0.05). Conclusion The probiotics, montmorillonite powder and interferon has exact clinical efficacy in the treatment of infantile autumn diarrhea, it can bi-directionally regulate intestinal flora, improve the intestinal environment, protect and repair damaged mucosa, promote tissue regeneration of digestive tract epithelial.

[Key words] Probiotics; Montmorillonite powder; Interferon; Infantile autumn diarrhea; Clinical application

小儿秋季腹泻是婴幼儿的多发病,以6个月~2岁为好发年龄,本病主要是由于肠道感染轮状病毒导致,主要表现为发热、多频次的腹瀉水样便或蛋花汤样便等症状,如不及时治疗,导致电解质紊乱、营养不良、脱水休克等,甚至威胁到婴幼儿的生命安全。目前尚无特效的治疗药物,治疗方法主要是采用对症治疗及病毒唑抗病毒治疗,但是止泻效果不令人满意。本文笔者观察微生态制剂、蒙脱石散剂、干扰素三联法治疗小儿秋季腹泻的临床疗效,获得良好的临床疗效,并探讨其作用机制,现将结果分析如下:

1 资料与方法

1.1 一般资料

本组共计纳入84例符合入组标准的秋季腹泻患儿,是本院2010年6月~2011年12月收治的,按随机数字表分为观察组42例和对照组42例,观察组中,男23例,女19例,平均年龄为(2.8±0.9)岁,平均病程为(2.1±0.6) d;对照组中,男20例,女22例,平均年龄为(2.9±0.8)岁,平均病程为(2.1±0.7) d;两组患儿一般资料差异无统计学意义(P > 0.05),具有可比性。

1.2 入组标准

1.2.1 纳入标准(1)符合《诸福棠实用儿科学》第7版中的小儿秋季腹泻的诊断标准;(2)≥1岁;(3)粪便轮状病毒检测均为阳性;(4)治疗期间未使用其他治疗药物。

1.2.2 排除标准(1)阿米巴痢疾、伤寒等疾病;(2)合并重大心、脑、肺、肾、血液病等器质性疾病者;(3)重度脱水,全身中毒症状严重者。

1.3 治疗方法

两组患儿均进行常规对症治疗与周密护理,包括口服补液,补充电解质,纠正酸碱平衡紊乱,卧床休息,清淡饮食。对照组在常规治疗基础上,口服蒙脱石散剂,1~3岁者每次1/3包、3次/d,﹥3岁者每次1/2包、3次/d,肌内注射重组人干扰素1 μg/(kg·次),每日1次;观察组在对照组基础上,口服枯草杆菌、肠球菌二联活菌多维颗粒剂(妈咪爱),<2周岁者每次1袋、1~2次/d,>2周岁者每次1~2袋、1~2次/d,3 d为1个疗程。

1.4 观察指标与疗效标准

观察治疗前后患儿症状改善情况,包括发热、大便次数、大便性状、粪便镜检等情况,计算患儿症状复常时间与出院时间。根据症状与粪便镜检评判两组治疗效果,分为治愈、好转、无效,(1)治愈:治疗后患儿症状及粪便镜检均恢复正常;(2)好转:治疗后,患儿症状明显改善,粪便镜检为阴性或阳性;(3)无效:治疗后,患儿症状无好转甚至恶化,粪便镜检为阳性。

1.5 统计学处理

采用SPSS 19.0进行统计分析,计量资料采用x±s表示,进行t检验,计数资料采用率表示,进行卡方分析,P < 0.05为差异具有统计学意义。

2 结果

2.1 两组临床疗效比较

观察组的治愈率、总有效率分别为61.90%和95.24%,对照组的治愈率、总有效率分别为28.57%、76.19%,观察组的治愈率明显高于对照组,χ2

猜你喜欢

微生态制剂干扰素临床应用
干扰素 你了解吗
干扰素在猪治疗病毒性疾病中的应用
微生态制剂对新生儿高胆红素血症的预防作用
血浆置换术联合口服微生态制剂治疗慢加急性肝衰竭患者的临床研究
浅析涌泉穴
渭南地区道地药材沙苑子应用研究
干扰素在猪治疗病毒性疾病中的应用
癌症的“克星”